EOLS - Evolus Inc
IEX Last Trade
15.91
0.080 0.503%
Share volume: 475,598
Last Updated: Fri 30 Aug 2024 09:59:57 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.87%
PREVIOUS CLOSE
CHG
CHG%
$15.83
0.08
0.51%
Fundamental analysis
12%
Profitability
5%
Dept financing
25%
Liquidity
75%
Performance
0%
Performance
5 Days
0.19%
1 Month
30.35%
3 Months
26.01%
6 Months
10.19%
1 Year
58.58%
2 Year
55.02%
Key data
Stock price
$15.91
DAY RANGE
N/A - N/A
52 WEEK RANGE
$7.44 - $16.29
52 WEEK CHANGE
$0.60
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/05/2024
Company detail
CEO: David Moatazedi
Region: US
Website: https://www.evolus.com
Employees: 261
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: https://www.evolus.com
Employees: 261
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
evolus, inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the united states. it offers jeuveau, a proprietary 900 kilodalton purified botulinum toxin type a formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. the company was founded in 2012 and is headquartered in newport beach, california.
Recent news